non-invasive-diagnostics
(2)
Eric Gornstein
Eric Gornstein is the Chief Executive Officer of Pearl Diagnostics, a Johns Hopkins spinout in Baltimore that makes MycoMEIA, the first FDA-cleared urine test for invasive aspergillosis. A biopharma commercialization veteran with more than 25 years leading product launches, partnering and deal-making across therapeutic areas, he joined Pearl in late 2025 to take the company from FDA clearance to the market and into Europe. Earlier he helped launch Radius Health's first product, Tymlos, and worked in business development and cell therapy partnerships at companies including bit.bio and Talaris Therapeutics.
Shlomi Madar
Shlomi Madar is the CEO of SpotitEarly, an Englewood, New Jersey biotech developing a non-invasive, breath-based multi-cancer screening test that pairs trained scent-detection dogs with a deep-learning platform. He holds a PhD in cancer research from the Weizmann Institute of Science and has spent more than fifteen years in life sciences and healthcare, previously serving as VP of Strategic Alliances at OncoHost and working on the Weizmann Institute's innovation arm. In May 2025 SpotitEarly closed a $20.3M Series A behind clinical results the company reports at roughly 94% sensitivity and specificity across four cancer types.